Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
The American Journal of Pathology|June 19, 2016
Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical ActivityMarina Cardó-Vila, Serena Marchiò, Masanori Sato, et al.Cancer|November 6, 2003
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinomaVassiliki A Papadimitrakopoulou, Lawrence E Ginsberg, Adam S Garden, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesotheliomaCharles Lu, Roman Perez-Soler, Bilal Piperdi, et al.Clinical Lung Cancer|June 11, 2014
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusionErminia Massarelli, Amir Onn, Edith M Marom, et al.Cancer|November 1, 2005
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancerRalph G Zinner, Frank V Fossella, Gregory W Gladish, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trialMerrill S Kies, Floyd Christopher Holsinger, J Jack Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.Cancer Prevention Research (Philadelphia, Pa.)|September 6, 2015
New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJean-Philippe Foy, Curtis R Pickering, Vassiliki A Papadimitrakopoulou, et al.Journal of the National Cancer Institute|January 17, 2012
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeNathan T Ihle, Lauren A Byers, Edward S Kim, et al.Cancer Discovery|May 16, 2012
The BATTLE trial: personalizing therapy for lung cancerEdward S Kim, Roy S Herbst, Ignacio I Wistuba, et al.Pageof 7